Eberhardt Medical Marijuana Lobby

The issue is no longer whether cannabis has medical relevance.

This proposal examines the intersection of trauma physiology, cannabinoid regulation, veteran healthcare policy, and behavioral misclassification within contemporary medical and institutional systems. Drawing from longitudinal lived observation alongside federal marijuana rescheduling proceedings, VA policy debates, and emerging cannabinoid research, the document argues that current regulatory frameworks often evaluate cannabis primarily through intoxication and risk-detection models while failing to account for nervous-system stabilization in trauma-affected populations. 

Specific examples explored include:

• documented gastrointestinal stabilization within approximately 15–20 minutes of CBD administration following adverse medication reactions,  
• the role of balanced CBD/THC ratios in reducing PTSD-associated hypervigilance and autonomic rigidity,  
• distinctions between pharmaceutical cannabinoid models and traditional low-dose botanical cannabis use,  
• and the risk of trauma-driven physiological responses being behaviorally misinterpreted as threat, instability, intoxication, or intent within institutional environments.  

The proposal further examines treatment sequencing problems experienced by medication-sensitive patients navigating layered psychiatric interventions, metabolic burden, chronic fatigue, inflammatory stress, and fragmented federal-state medical cannabis systems. 

Included within the archive are:

• congressional and policy-facing advocacy materials,
• references to DOJ/DEA Schedule III proceedings and VA marijuana recommendation proposals,
• a structured research discussion on autonomic regulation and trauma recovery,
• and an appendix previewing the related manuscript When Regulation Looks Like Risk: Chronic Cannabidiol Use, Trauma Recovery, and the Behavioral Misclassification Problem.    

This work contributes to emerging discussions in clinical forensics, trauma-informed governance, veteran healthcare reform, cannabinoid policy, behavioral interpretation systems, and longitudinal evidence-based patient observation.